Date

Thursday, June 30, 2022

Venue

Time

14:00 (GMT+7)

Jadwal acara

AGMS

1. Approval of the Annual Report 2021, including the Board of Commissioners Oversight Report and the Board of Directors' Accountability Report of the financial year 2021.
2. Ratification of the Annual Financial Statements for the financial year 2021; and to release and discharge of all responsibilities (volledig acquit et de charge) to all Board members for the management and supervision carried out in the financial year 2021.
3. Delegation of authority to Board of Commissioners to design, determine, and implement a remuneration system including honoraria, allowances, salaries, bonuses, and or other remuneration for Directors and Commissioners in 2022.
4. Election of a Public Accountant Firm to audit the company Financial Report of the financial year 2022, and authorise to determine the honorarium of the Public Accountant and the other requirements.

EGMS

1. Approval for the company to increase capital without pre-emptive rights by issuing new Series B shares with a nominal value of Rp. 50 (fifty Rupiah) per share to be issued from the portfolio, up to a maximum of 10% (ten per cent) of the total shares that have been issued and fully paid up up capital listed in the amendments to the articles of association of the company, as referred in the Financial Services Authority Regulation Number 14/POJK.04/2019 regarding the capital increase of a Public Company with Pre-emptive Rights, taking into account less dilution for Minority Shareholders.
2. Approval of changes to the company's authorized capital structure from the current composition consisting of shares with one nominal value of Rp. 100 (one hundred Rupiah) per share to shares with different nominal values ​​consisting of Series A shares with a nominal value of Rp. 100 (one hundred Rupiah)) per share and Series B shares with a nominal value of Rp 50 (fifty Rupiah) per share (shares issued for the capital increase without Pre-emptive Rights), where Series B shares have the same rights as Series A shares that have been circulated in the company.
3. Approval of the delegation of authority with the rights of substitution to Board of Directors to take all actions in connection with the decision to increase capital without Pre-emptive Rights, including but not limited to stating/writing the decision in deeds made before a Notary, to amend, adjust and/or rearrange the provisions in the Articles of Association of the company and its amendments or renewals, and subsequently to deliver notification of the resolutions of this Meeting to the competent authorities, and take all and any necessary actions, in accordance with the prevailing laws and regulations.